indication for semaglutide Indications oral Semaglutide for weight loss |

Published Phase 3 data shows Retatrutide achieving 28.7% average weight loss at 68 weeks surpassing either semaglutide or tirzepatide in comparable timeframes, with additional liver fat reduction and cardiovascular benefits

Participants with T2D at high risk for cardiovascular (CV) events ( n = 9,340) were randomised 1:1 to receive either liraglutide (1.8 mg daily

Prevention and therapy of chemotherapy-induced peripheral neuropathy: a review of recent findings

Semaglutide is commonly discussed as a GLP-1 receptor agonist research compound, while Tirzepatide is discussed as a dual GIP and GLP-1 receptor agonist research compound

Yindeedej V, Kittisangvara L